

## **SARS-CoV-2 and COVID-19**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus. There are six other coronaviruses that are known to infect humans. Four coronaviruses, HCoV-NL63, HCoV-HKU1, HCoV-229E, and HCoV-OC43 circulate worldwide and together are the second most common cause of the common cold.<sup>1,2</sup> Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infected 8096 people in 2003 resulting in 774 deaths.<sup>3</sup> After 2003 there has not been any further human to human transmission. Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in humans in 2012.<sup>4</sup> MERS-CoV continues to cause sporadic infection and outbreaks in the Arabian peninsula, as well as occasional other cases and outbreaks in other parts of the world linked to travelers to the Arabian peninsula.<sup>5</sup>

Bats were the source of SARS-CoV-1,<sup>6</sup> and are known to be a natural reservoir for related coronaviruses,<sup>7,8</sup> SARS-CoV-2 was likely circulating in bats for decades.<sup>9</sup> In late 2019, SARS-CoV-2 was first detected in humans and is established as the cause of the disease now designated coronavirus disease 2019 (COVID-19). Approximately 10-20% of persons with SARS-CoV-2 infection are asymptomatic.<sup>10,11</sup> In those who are symptomatic, there is a wide range of illness from those with mild symptoms such as runny nose to those with severe disease affecting particularly the respiratory tract with high mortality.<sup>12</sup> Most people with SARS-CoV-2 infection are asymptomatic or have mild-moderate symptoms not requiring hospitalization. In one study of a relatively healthy population, those with COVID-19 requiring hospital care was < 2%, and the mortality rate was < 0.1%.<sup>11</sup>

### **SARS-CoV-2 transmission and mortality**

The timing of peak SARS-CoV-2 transmission is primarily affected by seasonal patterns (i). The scale of SARS-CoV-2 transmission in a susceptible population is primarily determined by population density (ii). The mortality of COVID-19 is primarily determined by the age structure of the population (iii). Each of these important factors for SARS-CoV-2 transmission and mortality is non-modifiable.

(i) The timing of peak SARS-CoV-2 transmission is primarily affected by seasonal patterns

The four human coronaviruses (OC43, 229E, NL63, HKU1) are known to have a seasonal pattern of increased transmission.<sup>1</sup> The peak of the transmission wave in the United States is in the coldest months of the year, usually January. SARS-CoV-2 transmission appears to have a similar seasonal pattern of transmission to the other seasonal human coronaviruses.<sup>13</sup> There are numerous studies that show climate (season) is one of the most important factors for SARS-CoV-2 transmission.<sup>14-26</sup> In general, colder temperatures and less humidity are associated with increased SARS-CoV-2 transmission.

(ii) The scale of SARS-CoV-2 transmission is primarily determined by population density

The transmission of SARS-CoV-2 is strongly associated with population density, particularly population-weighted density.<sup>15-18, 24, 27-31</sup> In the United States, incidence and mortality are ten times higher in the most densely populated areas compared to the least densely populated areas.<sup>32,33</sup> The association between population density and SARS-CoV-2 transmission has been identified in Europe,<sup>34</sup> Italy,<sup>35</sup> India,<sup>36,37</sup> Argentina,<sup>38</sup> Turkey,<sup>39</sup> Algeria,<sup>40</sup> Brazil,<sup>22</sup> Japan,<sup>25</sup> and China.<sup>41</sup>

This is also evident in Canada. Provinces with the highest population density (e.g. Ontario) tend to have the highest number of cases. Within provinces (e.g. Ontario), regions with the highest population density tend to have the highest number of cases (e.g. Toronto).

(iii) The mortality of COVID-19 is primarily determined by the age structure of the population

Age is the most important risk factor for COVID-19 mortality. Compared to persons under age 40, persons over the age of 80 have a greater than 300 times chance of dying from COVID-19.<sup>42</sup> The infection fatality ratio (IFR) in persons over 80 is approximately 1000 times the IFR in those under 20.<sup>43</sup> In Canada, 68% of deaths are in persons over 80, 87.5% of deaths are in persons over 70, and > 95% of deaths are in persons over 60.<sup>13</sup>

The risk of death due to COVID-19 in persons under 60 is very small.<sup>44</sup> In Canada, there have been 1,010 COVID-19 related deaths in persons < 60 years old as of April 16, 2021.<sup>13</sup> In Canada

in 2018 there were 1,191 motor vehicle fatalities in persons under 55.<sup>45</sup> So, the risk of death due to COVID-19 in persons < 60 is less than the risk of death due to a motor vehicle fatality.

### **Asymptomatic transmission**

A *British Medical Journal* editorial concisely summarizes the risk of asymptomatic transmission: “The transmission rates to contacts within a specific group (secondary attack rate) may be 3-25 times lower for people who are asymptomatic than for those with symptoms.”<sup>46</sup> This is consistent with the conclusions from several peer-reviewed systematic reviews and meta-analyses.<sup>47-50</sup>

To further exemplify the risk of asymptomatic transmission, it is useful to look specifically at a few large or comprehensive studies. A very large study in Wuhan China of 9,899,828 city residents found 300 asymptomatic cases but there were no positive tests amongst 1,174 close contacts of asymptomatic cases.<sup>51</sup> Similarly, a very thorough study of 100 cases from Taiwan, found that “none of the 9 asymptomatic case patients transmitted a secondary case.”<sup>52</sup>

Household transmission is one of the most important modes of transmission. In a meta-analysis of household transmission, which included 54 studies and 77 758 participants,<sup>53</sup> transmission from asymptomatic cases was 0.7% compared to 18% transmission from symptomatic cases. In other words, symptomatic transmission was roughly 25 times higher than asymptomatic transmission.

Asymptomatic transmission does occur but the rates of transmission from asymptomatic persons is substantially less than from symptomatic persons and does not warrant being considered a significant contributor to the overall transmission burden.

### **Evidence for lockdown measures, such as physical/social distancing, to control SARS-CoV-2 transmission**

Almost all of the research done prior to 2020 examining the effectiveness of interventions such as avoiding crowding to control respiratory tract infections was done with influenza. Prior to 2020, social distancing was a term that included quarantine, school closures, work closures as well as avoiding crowding.<sup>54</sup>

As noted in a recent systemic review, “clear biological and epidemiologic rationale supports the potential effectiveness of social distancing measures”<sup>55</sup> in the control of viral respiratory tract infections. However, the actual evidence for avoiding crowding by the general public for the control of viral respiratory tract infections is negligible.

A 2019 WHO review<sup>54</sup> of non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza found only three studies<sup>56-58</sup> relevant to “avoiding crowding”. In all three studies the quality of evidence was rated as very low. Two of those studies were retrospective analysis of the 1918 pandemic<sup>56-57</sup>, both published in 2007. The limitations of studies done almost a century after an event should be self-evident, and hence the quality of that evidence is rated as very low. Importantly, in reference to “avoiding crowding” the WHO document notes:<sup>54</sup>

*Ethical considerations*

In urban locations it can be difficult to avoid crowding without considerable social costs.

Modification, postponement or cancellation of mass gatherings may have cultural or religious considerations, in addition to public health aspects.

*Knowledge gaps*

There are still major gaps in our understanding of person-to-person transmission dynamics. Reducing mass gatherings is likely to reduce transmission in the community, but the potential effects are difficult to predict with accuracy. Large-scale RCTs [randomized controlled trials] are unlikely to be feasible.

A 2020 Cochrane systematic review<sup>59</sup> “found only one RCT [randomized controlled trial] of quarantine, and no trials of screening at entry ports or physical distancing [emphasis added].” Since there is a complete absence of high-quality evidence regarding physical distancing, the authors state: “Physical distancing represents another major research gap which needs to be addressed expediently, especially within the context of the COVID-19 pandemic setting as well as in future epidemic settings.”<sup>59</sup>

In summary, there is an absence of high-quality evidence, such as randomized-controlled trials, that prove the effectiveness of lockdown measures to avoid crowding in particular groups or contexts.

### **Evidence for masks to prevent the spread of SARS-CoV-2**

In short, and as stated by the World Health Organization (WHO), “there is only limited and inconsistent scientific evidence to support the effectiveness of masking of healthy people in the community to prevent infection with respiratory viruses, including SARS-CoV-2”.<sup>60</sup>

The best evidence for any medical intervention comes from large randomized controlled trials or meta-analysis of randomized trials. There are no randomized controlled trials or meta-analysis of randomized controlled trials that support the effectiveness of masking of healthy people in the community to prevent infection with respiratory viruses, including SARS-CoV-2.

There is only one published randomized controlled trial on the effectiveness of masking of healthy people in the community to prevent infection with SARS-CoV-2. That study found there was no significant difference in SARS-CoV-2 infection rates between those who wore masks and those who did not wear masks.<sup>61</sup>

Three recent meta-analyses show no benefit of masking healthy people in the community to prevent infection with respiratory viruses. Cochrane systematic reviews are widely recognized in the medical community as authoritative. A 2020 Cochrane meta-analysis of masks versus no masks in preventing viral respiratory illness found no difference in preventing influenza-like illness or laboratory confirmed illness.<sup>62</sup> Similarly, another meta-analysis published in 2020 showed that masks make no difference in preventing pandemic influenza in nonhealthcare settings.<sup>63</sup> Another meta-analysis by the WHO in 2019 also failed to show a substantial protective effect of face masks.<sup>64</sup>

When the analysis is limited to the strongest types of evidence (randomized trials and meta-analyses of randomized trials), there is no evidence that healthy persons wearing masks in non-healthcare settings prevents the spread of SARS-CoV-2.

In the absence of evidence from randomized controlled trials and meta-analyses, the WHO's report on masking from December 1, 2020<sup>60</sup> references a number of other types of studies that report to show that healthy persons wearing masks in non-healthcare settings prevents the spread of SARS-CoV-2. However, these studies have significant limitations that need to be considered.

The majority of the studies referenced by the WHO are ecological studies,<sup>65-86</sup> also called correlational studies. The ecological studies referenced by WHO compare mask use and COVID-19 rates between geographic region, such as country, state, or city. The descriptive analysis of these rates does not provide an evidentiary base for concluding causation. Ecological studies have “many methodologic problems that severely limit causal inference, including ecologic and cross-level bias, problems of confounder control, within-group misclassification, lack of adequate data, temporal ambiguity, collinearity, and migration across groups.”<sup>87</sup> The WHO report also acknowledges those studies “have important limitations to consider”.<sup>60, 88-90</sup>

Cohort studies,<sup>91</sup> case control,<sup>92-94</sup> and case series<sup>95-97</sup> are all referenced in the WHO document, but these study types are considered much weaker than randomized controlled trials or meta-analysis. Due to the limitation of the study designs, particularly bias and confounding, the true effect of masking is uncertain. Many of these studies also have limited generalizability. For example, a study looking at secondary transmission of SARS-CoV-2 in households<sup>91</sup> has limited generalizability to universal masking in the wider general public. The findings from case series of persons who traveled on the same flight<sup>95, 96</sup> cannot be generalized to universal masking.

Finally, a comment should be made on the study<sup>98</sup> by Chu et al. as that study is referenced by the WHO and has been widely cited in the media. As noted in the 2020 Cochrane review referenced above, the Chu et al. study “has been criticised for several reasons: use of an outdated ‘Risk of bias’ tool; inaccuracy of distance measures; and not adequately addressing multiple sources of bias, including recall and classification bias and in particular confounding. Confounding is very likely, as preventive behaviours such as mask use, social distancing, and hand hygiene are correlated behaviours, and hence any effect estimates are likely to be overly optimistic.”<sup>62</sup>

In summary, there is “inconsistent scientific evidence to support the effectiveness of masking of healthy people in the community to prevent infection with respiratory viruses, including SARS-CoV-2”.<sup>60</sup> Studies that support the effectiveness of masking are of poorer methodological quality

and hence provide weaker evidence. Randomized controlled trial and meta-analysis, which provide stronger scientific evidence, do not support the effectiveness of masking of healthy people in the community to prevent infection with respiratory viruses, including SARS-CoV-2.

## REFERENCES CITED

1. Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, Watson JT. Human coronavirus circulation in the United States 2014-2017. *J Clin Virol*. 2018 Apr;101:52-56.
2. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends Microbiol*. 2016 Jun;24(6):490-502.
3. <https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003>
4. Dawson P, Malik MR, Parvez F, Morse SS. What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review. *Vector Borne Zoonotic Dis*. 2019 Mar;19(3):174-192.
5. [https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab\\_1](https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1)
6. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol*. 2016 Aug;14(8):523-34.
7. Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. *Emerg Infect Dis*. 2006 Dec;12(12):1834-40.
8. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. Bats are natural reservoirs of SARS-like coronaviruses. *Science*. 2005 Oct 28;310(5748):676-9.
9. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nat Microbiol*. 2020 Nov;5(11):1408-1417.
10. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA; Public Health–Seattle and King County and CDC COVID-19 Investigation Team.

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med.* 2020 May 28;382(22):2081-2090.

11. Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM, McGinnis MB, Olson N, Houskamp D, Fenequito R, Burgess TH, Armstrong AW, DeLong G, Hawkins RJ, Gillingham BL. An Outbreak of Covid-19 on an Aircraft Carrier. *N Engl J Med.* 2020 Dec 17;383(25):2417-2426.
12. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med.* 2020 Dec 17;383(25):2451-2460.
13. Coronavirus disease 2019 (COVID-19): Epidemiology update  
<https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>
14. Benedetti F, Pachetti M, Marini B, Ippodrino R, Gallo RC, Ciccozzi M, Zella D. Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas. *J Transl Med.* 2020 Jun 23;18(1):251.
15. Spada A, Tucci FA, Ummarino A, Ciavarella PP, Calà N, Troiano V, Caputo M, Ianzano R, Corbo S, de Biase M, Fascia N, Forte C, Gambacorta G, Maccione G, Prencipe G, Tomaiuolo M, Tucci A. Structural equation modeling to shed light on the controversial role of climate on the spread of SARS-CoV-2. *Sci Rep.* 2021 Apr 16;11(1):8358.
16. Castilla J, Fresán U, Trobajo-Sanmartín C, Guevara M. Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain. *Int J Environ Res Public Health.* 2021 Mar 4;18(5):2578.
17. Afshordi N, Holder B, Bahrami M, Lichtblau D. Diverse local epidemics reveal the distinct effects of population density, demographics, climate, depletion of susceptibles, and intervention in the first wave of COVID-19 in the United States.  
<https://arxiv.org/pdf/2007.00159.pdf>
18. Riley P, Riley A, Turtle J, Ben-Nun M. COVID-19 Deaths: Which Explanatory Variables Matter the Most?  
<https://www.medrxiv.org/content/10.1101/2020.06.11.20129007v1.abstract>
19. Coro G. A global-scale ecological niche model to predict SARS-CoV-2 coronavirus infection rate. *Ecol Modell.* 2020 Sep 1;431:109187.
20. Tzampoglou P, Loukidis D. Investigation of the Importance of Climatic Factors in COVID-19 Worldwide Intensity. *Int J Environ Res Public Health.* 2020 Oct 22;17(21):7730.
21. Vantarakis A, Chatziprodromidou I, Apostolou T. COVID-19 and Environmental factors. PRISMA-compliant systematic review.  
<https://www.medrxiv.org/content/10.1101/2020.05.10.20069732v1.abstract>



22. Pequeno P, Mendel B, Rosa C, Bosholn M, Souza JL, Baccaro F, Barbosa R, Magnusson W. Air transportation, population density and temperature predict the spread of COVID-19 in Brazil. *PeerJ*. 2020 Jun 3;8:e9322.
23. Liu J, Zhou J, Yao J, Zhang X, Li L, Xu X, He X, Wang B, Fu S, Niu T, Yan J, Shi Y, Ren X, Niu J, Zhu W, Li S, Luo B, Zhang K. Impact of meteorological factors on the COVID-19 transmission: A multi-city study in China. *Sci Total Environ*. 2020 Jul 15;726:138513.
24. Diao Y, Kodera S, Anzai D, Gomez-Tames J, Rashed EA, Hirata A. Influence of population density, temperature, and absolute humidity on spread and decay durations of COVID-19: A comparative study of scenarios in China, England, Germany, and Japan. *One Health*. 2020 Dec 11;12:100203.
25. Rashed EA, Kodera S, Gomez-Tames J, Hirata A. Influence of Absolute Humidity, Temperature and Population Density on COVID-19 Spread and Decay Durations: Multi-Prefecture Study in Japan. *Int J Environ Res Public Health*. 2020 Jul 24;17(15):5354.
26. Byun WS, Heo SW, Jo G, Kim JW, Kim S, Lee S, Park HE, Baek JH. Is coronavirus disease (COVID-19) seasonal? A critical analysis of empirical and epidemiological studies at global and local scales. *Environ Res*. 2021 Mar 9;196:110972.
27. Chen K, Li Z. The spread rate of SARS-CoV-2 is strongly associated with population density. *J Travel Med*. 2020 Dec 23;27(8)
28. Ives AR, Bozzuto C. Estimating and explaining the spread of COVID-19 at the county level in the USA. *Commun Biol*. 2021 Jan 5;4(1):60.
29. Sy KTL, White LF, Nichols BE. Population density and basic reproductive number of COVID-19 across United States counties.  
<https://www.medrxiv.org/content/10.1101/2020.06.12.20130021v1.full.pdf>
30. Hass FS, Jokar Arsanjani J. The Geography of the Covid-19 Pandemic: A Data-Driven Approach to Exploring Geographical Driving Forces. *Int J Environ Res Public Health*.
31. Al-Gahtani, S., Shoukri, M. and Al-Eid, M. (2021) Predictors of the Aggregate of COVID-19 Cases and Its Case-Fatality: A Global Investigation Involving 120 Countries. *Open Journal of Statistics*, 11, 259-277.
32. Rubin D, Huang J, Fisher BT, Gasparrini A, Tam V, Song L, Wang X, Kaufman J, Fitzpatrick K, Jain A, Griffis H, Crammer K, Morris J, Tasian G. Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. *JAMA Netw Open*. 2020 Jul 1;3(7):e2016099.

33. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, Parsonnet J, Chertow GM. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. *Lancet*. 2020 Sep 25;396(10259):1335-44.
34. Garland P, Babbitt D, Bondarenko M, Sorichetta A, Tatem AJ, Johnson O. The COVID-19 pandemic as experienced by the individual.  
<https://arxiv.org/pdf/2005.01167.pdf>
35. Ilardi A, Chieffi S, Iavarone A, Ilardi CR. SARS-CoV-2 in Italy: Population Density Correlates with Morbidity and Mortality. *Jpn J Infect Dis*. 2021 Jan 22;74(1):61-64.
36. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, Jain R, Agrawal S, Juneja S, Imad S, Kolthur-Seetharam U. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. *Lancet Glob Health*. 2021 Feb;9(2):e110-e111.
37. Bhadra A, Mukherjee A, Sarkar K. Impact of population density on Covid-19 infected and mortality rate in India. *Model Earth Syst Environ*. 2020 Oct 14:1-7.
38. Macchia A, Ferrante D, Battistella G, Mariani J, González Bernaldo de Quirós F. COVID-19 among the inhabitants of the slums in the city of Buenos Aires: a population-based study. *BMJ Open*. 2021 Jan 20;11(1):e044592.
39. Baser O. Population density index and its use for distribution of Covid-19: A case study using Turkish data. *Health Policy*. 2021 Feb;125(2):148-154.
40. Kadi N, Khelfaoui M. Population density, a factor in the spread of COVID-19 in Algeria: statistic study. *Bull Natl Res Cent*. 2020;44(1):138.
41. Copiello S, Grillenzoni C. The spread of 2019-nCoV in China was primarily driven by population density. Comment on "Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China" by Zhu et al. *Sci Total Environ*. 2020 Nov 20;744:141028.
42. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020 Aug;584(7821):430-436.
43. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020 Jun;20(6):669-677.

44. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *Environ Res.* 2020 Sep;188:109890.
45. <https://tc.canada.ca/en/road-transportation/motor-vehicle-safety/canadian-motor-vehicle-traffic-collision-statistics-2018>
46. Pollack AM, Lancaster J. Asymptomatic transmission of covid-19. *BMJ.* 2020;371:m4851.
47. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med.* 2020 Sep 22;17(9):e1003346.
48. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. *JAMMI.* 5.4, 2020. 223-234.
49. Koh WC, Naing L, Chaw L, Rosledzana MA, Alikhan MF, Jamaludin SA, Amin F, Omar A, Shazli A, Griffith M, Pastore R, Wong J. What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. *PLoS One.* 2020 Oct 8;15(10):e0240205.
50. Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. Defining the role of asymptomatic and pre-symptomatic SARS-CoV-2 transmission - a living systematic review. *Clin Microbiol Infect.* 2021 Jan 20:S1198-743X(21)00038-0.
51. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, Huang Y, Wang T, Li L, Lu K, Jiang H, Gong Y, Xu H, Shen X, Tian Q, Lv C, Song F, Yin X, Lu Z. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. *Nat Commun.* 2020 Nov 20;11(1):5917.
52. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH; Taiwan COVID-19 Outbreak Investigation Team. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern Med.* 2020 Sep 1;180(9):1156-1163.
53. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2020 Dec 1;3(12):e2031756.
54. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza; 2019 <https://apps.who.int/iris/bitstream/handle/10665/329439/WHO-WHE-IHM-GIP-2019.1-eng.pdf>


55. Fong MW, Gao H, Wong JY, Xiao J, Shiu EYC, Ryu S, Cowling BJ. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings - Social Distancing Measures. *Emerg Infect Dis.* 2020 May;26(5):976-984.
56. Hatchett RJ, Mecher CE, Lipsitch M. Public health interventions and epidemic intensity during the 1918 influenza pandemic. *Proc Natl Acad Sci U S A.* 2007;104(18):7582-7.
57. Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, Stern AM et al. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. *JAMA.* 2007;298(6):644-54.
58. Staff M, Torres MI. An influenza outbreak among pilgrims sleeping at a school without purpose built overnight accommodation facilities. *Commun Dis Intell Q Rep.* 2011;35(1):10-5.
59. Jefferson T DMC, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database of Systematic Reviews* 2020;(11):CD006207.
60. World Health Organization. Mask use in the context of COVID-19. Interim guidance. 1 December 2020.  
WHO reference number: WHO/2019-nCoV/IPC\_Masks/2020.5  
[https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-\(2019-ncov\)-outbreak](https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak)
61. Bundgaard H, J. B, Raaschou-Pedersen D, von Buchwald C, Todsén T, Norsk J. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers. *Ann Intern Med.* 2020.
62. Jefferson T DMC, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database of Systematic Reviews* 2020;(11):CD006207.
63. Xiao J, Shiu EYC, Gao H, Wong JY, Fong MW, Ryu S, Cowling BJ. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings - personal protective and environmental measures. *Emerging Infectious Diseases* 2020;26(5):967-75.
64. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza; 2019 <https://apps.who.int/iris/bitstream/handle/10665/329439/WHO-WHE-IHM-GIP-2019.1-eng.pdf> (accessed January 28, 2021)
65. Chiang CH, Chiang CH, Chiang CH, Chen YC. The Practice of Wearing Surgical Masks during the COVID-19 Pandemic. *Emerg Infect Dis.* 2020;26(8):1962.

66. Cheng VC, Wong SC, Chuang VW, So SY, Chen JH, Sridhar S, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. *J Infect.* 2020;81(1):107-14.
67. Bo Y, Guo C, Lin C, et al. Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. *Int J Infect Dis.* 2020; 102: 247–253.
68. Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. *Health Aff (Millwood).* 2020;39(8):1419-25.
69. Gallaway MS, Rigler J, Robinson S, Herrick K, Livar E, Komatsu KK, et al. Trends in COVID-19 Incidence After Implementation of Mitigation Measures - Arizona, January 22-August 7, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(40):1460-3.
70. Rader B, White LF, Burns MR, Chen J, Brilliant J, Cohen J, et al. Mask Wearing and Control of SARS-CoV-2 Transmission in the United States. *MedRxiv.* 2020. doi: 10.1101/2020.08.23.20078964.
71. Matzinger P, Skinner J. Strong impact of closing schools, closing bars and wearing masks during the Covid-19 pandemic: results from a simple and revealing analysis. *MedRxiv.* 2020. doi: 10.1101/2020.09.26.20202457.
72. Kenyon C. Widespread use of face masks in public may slow the spread of SARS CoV-2: 1 an ecological study. *MedRxiv.* 2020. doi: 10.1101/2020.03.31.20048652.
73. Leffler CT, Ing E, Lykins JD, Hogan MC, McKeown CA, Grzybowski A. Association of Country-wide Coronavirus Mortality with Demographics, Testing, Lockdowns, and Public Wearing of Masks. *Am J Trop Med Hyg.* 2020. doi: 10.4269/ajtmh.20-1015.
74. Lan F-Y, Christophi C, Buley J, Lliaki E, Bruno-Murtha L, Sayah A, et al. Effects of universal masking on Massachusetts healthcare workers' COVID-19 incidence. *MedRxiv.* 2020. doi: 10.1101/2020.08.09.20171173.
75. Aravindakshan A, Boehnke J, Gholami E, Nayak A. Mask-Wearing During the COVID-19 Pandemic. *MedRxiv.* 2020. doi: 10.1101/2020.09.11.20192971.
76. Pletz M, Steiner A, Kesselmeier M, Loeffler B, Trommer S, Weis S, et al. Impact of universal masking in health care and community on SARS-CoV-2 spread. *MedRxiv.* 2020. doi: 10.1101/2020.09.02.20187021.
77. Fortaleza C, et al. Impact of nonpharmaceutical governmental strategies for prevention and control of COVID-19 in São Paulo State, Brazil. *MedRxiv.* 2020. doi: 10.1101/2020.08.23.20180273.

78. Karaivanov A, Lu SE, Shigeoka H, Chen C, Pamplona S. Face Masks, Public Policies and Slowing the Spread of COVID-19: Evidence from Canada. *MedRxiv*. 2020. doi: 10.1101/2020.09.24.20201178.
79. Miyazawa D, Kaneko G. Face mask wearing rate predicts country's COVID-19 death rates: with supplementary state-by-state data in the United States. *MedRxiv*. 2020. doi: 10.1101/2020.06.22.20137745.
80. Mitze T, Kosfeld R, Rode J, Walde K. Face Masks Considerably Reduce Covid-19 Cases in Germany. *MedRxiv*. 2020. doi: 10.1101/2020.06.21.20128181.
81. Maloney M, Rhodes N, Yarnold P. Mask mandates can limit COVID spread: Quantitative assessment of month-over-month effectiveness of governmental policies in reducing the number of new COVID-19 cases in 37 US States and the District of Columbia. *MedRxiv*. 2020. doi: 10.1101/2020.10.06.20208033.
82. Sruthi C, Biswal M, Saraswat B, Joshi H, Prakash M. How Policies on Restaurants, Bars, Nightclubs, Masks, Schools, and Travel Influenced Swiss COVID-19 Reproduction Ratios. *MedRxiv*. 2020. doi: 10.1101/2020.10.11.20210641.
83. Shacham e, Scroggins S, Ellis M, Garza A. Association of County-Wide Mask Ordinances with Reductions in Daily CoVID-19 Incident Case Growth in a Midwestern Region Over 12 Weeks. *MedRxiv*. 2020. doi: 10.1101/2020.10.28.20221705.
84. Chernozhukov V, Kasahara H, Schrimpf P. Causal Impact of Masks, Policies, Behavior on Early Covid-19 Pandemic in the U.S. *J Econom*. 2020. doi: 10.1016/j.jeconom.2020.09.003.
85. Research GS. Face Masks and GDP. 2020. (<https://www.goldmansachs.com/insights/pages/face-masks-and-gdp.html> accessed 21 November 2020).
86. Scott N, Saul A, Spelman T, Stooze M, Pedrana A, Saeri A. The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city. 2020. (Available at SSRN:<http://dx.doi.org/10.2139/ssrn.3714648> accessed 29 November 2020).
87. Morgenstern H. Ecologic studies in epidemiology: concepts, principles, and methods. *Annu Rev Public Health*. 1995;16:61-81.
88. Piantadosi S, Byar DP, Green SB. The ecological fallacy. *Am J Epidemiol*. 1988;127(5):893-904.
89. Clifford GD, Long WJ, Moody GB, Szolovits P. Robust parameter extraction for decision support using multimodal intensive care data. *Philos Trans A Math Phys Eng Sci*. 2009 Jan 28; 367(1887): 411–429.

90. Dufault B, Klar N. The quality of modern cross-sectional ecologic studies: a bibliometric review. *Am J Epidemiol.* 2011;174(10):1101-7.
91. Wang Y, Tian H, Zhang L, Zhang M, Guo D, Wu W, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health.* 2020; 5(5): e002794.
92. Doung-ngern P, Suphanchaimat R, Panjangampatthana A, Janekrongtham C, Ruampoom D, Daochaeng N. Associations between mask-wearing, handwashing, and social distancing practices and risk 2 of COVID-19 infection in public: a case-control study in Thailand. *Emerg Infect Dis.* 2020;26(11):2607-2616.
93. Lau JT, Tsui H, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. *Emerg Infect Dis.* 2004;10(4):587-92.
94. Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, et al. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. *Emerg Infect Dis.* 2004;10(2):210-6.
95. Chen J, He H, Cheng W. Potential transmission of SARS-CoV-2 on a flight from Singapore to Hangzhou, China: An epidemiological investigation. *Travel Med Infect Dis.* 2020; 36: 101816.
96. Schwartz KL, Murti M, Finkelstein M, Leis JA, Fitzgerald-Husek A, Bourns L, et al. Lack of COVID-19 transmission on an international flight. *CMAJ.*
97. Hendrix MJ, Walde C, Findley K, Trotman R. Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(28):930-2.
98. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet.* 2020 Jun 27;395(10242):1973-1987.



, MD FRCPC  
April 22, 2021